Company intelligence / Profile preview

Heuron

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Heuron has developed and commercialized AI-powered solutions for the diagnosis of neurological diseases, including an FDA-designated "Innovative Medical Device" software for Parkinson’s disease. Their platform is used to analyze 3D MRIs to detect neuromelanin changes associated with neurodegenerative conditions. The company is conducting retrospective clinical trials and aims to expand regulatory approvals.

Therapeutic areas: Neurology
Modalities: DeviceSoftware (AI-based diagnostic software)
Industry: Medical Imaging

Partnerships

Not explicitly listed; recent collaborations with Boston Medical Center experts as advisors suggest academic/clinical partnerships.

Beyond the preview

Go deeper on Heuron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heuron.

Explore the full profile